HomeInsightsStock Comparison

Aarti Drugs Ltd vs Venus Remedies Ltd Stock Comparison

Aarti Drugs Ltd vs Venus Remedies Ltd Stock Comparison

Last Updated on: Jul 18, 2025

Key Highlights

  • The Latest Trading Price of Aarti Drugs Ltd is ₹ 517 as of 18 Jul 10:00.
  • The P/E Ratio of Aarti Drugs Ltd changed from 8.3 on March 2020 to 23.3 on March 2024 . This represents a CAGR of 22.93% over 5 yearsThe P/E Ratio of Venus Remedies Ltd changed from 5.5 on March 2021 to 15.3 on March 2024 . This represents a CAGR of 29.15% over 4 years.
  • The Market Cap of Aarti Drugs Ltd changed from ₹ 1178 crore on March 2020 to ₹ 3988 crore on March 2024 . This represents a CAGR of 27.61% over 5 yearsThe Market Cap of Venus Remedies Ltd changed from ₹ 27.77 crore on March 2020 to ₹ 436.3 crore on March 2024 . This represents a CAGR of 73.48% over 5 years.
  • The revenue of Aarti Drugs Ltd for the Mar '25 is ₹ 678.63 crore as compare to the Dec '24 revenue of ₹ 568.5 crore. This represent the growth of 19.37% The revenue of Venus Remedies Ltd for the Mar '25 is ₹ 201.73 crore as compare to the Dec '24 revenue of ₹ 188.8 crore. This represent the growth of 6.85%.
  • The ebitda of Aarti Drugs Ltd for the Mar '25 is ₹ 95.2 crore as compare to the Dec '24 ebitda of ₹ 73.62 crore. This represent the growth of 29.31% The ebitda of Venus Remedies Ltd for the Mar '25 is ₹ 35.76 crore as compare to the Dec '24 ebitda of ₹ 30.3 crore. This represent the growth of 18.02%.
  • The net profit of Aarti Drugs Ltd changed from ₹ 47.97 crore to ₹ 62.77 crore over 8 quarters. This represents a CAGR of 14.39% The net profit of Venus Remedies Ltd changed from ₹ 1.18 crore to ₹ 21 crore over 8 quarters. This represents a CAGR of 321.86% .
  • The Dividend Payout of Aarti Drugs Ltd changed from 3.43 % on March 2020 to 6.48 % on March 2024 . This represents a CAGR of 13.57% over 5 yearsThe Dividend Payout of Venus Remedies Ltd changed from 0 % on March 2020 to 0 % on March 2024 . This represents a CAGR of 0.0% over 5 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Aarti Drugs Ltd

  • Aarti Drugs Limited (ADL), incorporated in September, 1984 is a prominent manufacturer of APIs, Pharma Intermediates, and Specialty Chemicals.
  • The Company operates as part of the Aarti Group, a conglomerate with a net worth of USD 900 million.
  • With over 50 compounds for Antibiotics, Anti Protozoal, Anti-Inflammatory, Anti-diabetic, Anti Fungal and Cardioprotectant therapeutic segments, the Company has emerged as market leader in APIs.
  • It has a wholly-owned subsidiary called Pinnacle Life Science Private Limited which operates in the field of manufacturing formulations. The Company has two R&D divisions, one in Tarapur and the other in Turbhe, Maharashtra.
  • It has 3 subsidiaries, namely, Pinnacle Life Science Private Limited, Aarti Speciality Chemicals Limited and Pinnacle Chile SpA (foreign subsidiary).

About Venus Remedies Ltd

  • Incorporated in 1989 Venus Remedies Ltd (formerly known Venus Glucose Pvt Ltd), was converted into Public Limited Company in 1994 and then changed into Venus Remedies Limited.
  • The Company was promoted and managed by Chaudhary & Family.
  • The Company is one of the handful player in pharmaceutical sector to launch injectables globally.
  • It has manufacturing facilities in Panchkula and Baddi , and research and development centre under the name of Venus Medicine Research Centre (in India).
  • In priority, the Company was mainly engaged in I/V Fluids & Injectables, Ceftazidime, Amlodipine, Gliclazide, Lisinopril, etc. The production was started in 1991 with Intravenous/Intramuscular injectible forms at Panchkula district at Haryana.

Aarti Drugs Ltd News Hub

News

Aarti Drugs to convene board meeting

Aarti Drugs will hold a meeting of the Board of Directors of the Company on 18 July 2025. ...

Read more

16 Jul 2025 10:24

News

Aarti Drugs to convene board meeting

Aarti Drugs will hold a meeting of the Board of Directors of the Company on 6 May 2025. Po...

Read more

30 Apr 2025 11:38

News

Aarti Drugs receives affirmation in credit ratings from ICRA

Aarti Drugs has received reaffirmation in credit rating at ICRA AA-; Stable/ ICRA A1+ for ...

Read more

31 Jan 2025 19:10

News

Aarti Drugs gains as PAT rises to Rs 37 cr in Q3; declares dividend of Re 1/sh

Revenue from operations declined 6.44% to Rs 568.50 crore in third quarter of FY25 as comp...

Read more

30 Jan 2025 12:14

News

Board of Aarti Drugs recommends Interim Dividend

Aarti Drugs announced that the Board of Directors of the Company at its meeting held on 29...

Read more

29 Jan 2025 17:03

News

Aarti Drugs to conduct board meeting

Aarti Drugs will hold a meeting of the Board of Directors of the Company on 29 January 202...

Read more

23 Jan 2025 11:25

Venus Remedies Ltd News Hub

News

Venus Remedies to hold AGM

Venus Remedies announced that the 36th Annual General Meeting(AGM) of the company will be ...

Read more

10 Jul 2025 09:50

News

Venus Remedies to conduct board meeting

Venus Remedies will hold a meeting of the Board of Directors of the Company on 8 July 2025...

Read more

27 Jun 2025 16:28

News

Venus Remedies spurts after Q4 PAT climbs 100% YoY to Rs 21 cr

However, revenue from operations decreased marginally to Rs 194.97 crore in Q4 FY25, as ag...

Read more

27 May 2025 11:37

News

Venus Remedies to hold board meeting

Venus Remedies will hold a meeting of the Board of Directors of the Company on 26 May 2025...

Read more

17 May 2025 16:57

News

Venus Remedies jumps as investigational drug secures QIDP tag from USFDA

The drug is intended for the treatment of bloodstream infections caused by polymyxin B (PM...

Read more

17 Apr 2025 10:23

News

Venus Remedies gains on strategic MET-X partnership

MET-X, a metallo-beta-lactamase (MBL) inhibitor, targets drug-resistant Gram-negative bact...

Read more

25 Feb 2025 11:26

SWOT Analysis Of Venus Remedies Ltd

Strength

2

S

Weakness

2

W

Opportunity

0

O

Threats

0

T

SWOT Analysis Of Aarti Drugs Ltd

Strength

2

S

Weakness

1

W

Opportunity

0

O

Threats

0

T

BlinkX Score for Venus Remedies Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Aarti Drugs Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Aarti Drugs Ltd and Venus Remedies Ltd

Which company has a larger market capitalization, Aarti Drugs Ltd or Venus Remedies Ltd?

Market cap of Aarti Drugs Ltd is 4,741 Cr while Market cap of Venus Remedies Ltd is 736 Cr

What are the key factors driving the stock performance of Aarti Drugs Ltd and Venus Remedies Ltd?

The stock performance of Aarti Drugs Ltd and Venus Remedies Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Aarti Drugs Ltd and Venus Remedies Ltd?

As of July 18, 2025, the Aarti Drugs Ltd stock price is INR ₹515.75. On the other hand, Venus Remedies Ltd stock price is INR ₹550.95.

How do dividend payouts of Aarti Drugs Ltd and Venus Remedies Ltd compare?

To compare the dividend payouts of Aarti Drugs Ltd and Venus Remedies Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions